Shanghai-headquartered biopharmaceutical company LianBio has raised $310 million in an oversubscribed crossover financing round co-led by US healthcare-focused investment firm RA Capital and Venrock Healthcare Capital Partners, besides CMG-SDIC Capital – a 10 billion yuan ($1.5 billion) fund jointly launched by state-owned SDIC Fund and China Merchants Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
